SCHEMBL1521805

SCHEMBL1521805

CNc1ncc2c(n1)N(C1CCOC1)C(=O)N(c1ccc(F)c(NC(=O)Nc3cnn(C(C)(C)C)c3)c1)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.38
BRAF P15056 2/20 0.38
KRAS P01116 1/20 0.38
RAF1 P04049 1/20 0.38
MAP2K2 P36507 1/20 0.38
MAP2K1 Q02750 1/20 0.38
EGFR P00533 11/20 0.38
FGFR4 P22455 7/20 0.38
FGFR1 P11362 4/20 0.38
FGFR2 P21802 4/20 0.38
FGFR3 P22607 4/20 0.38
PDGFRB P09619 3/20 0.38
PDGFRA P16234 3/20 0.38
FYN P06241 2/20 0.38
MAPK1 P28482 2/20 0.38
EPHB3 P54753 2/20 0.38
PRKACA P17612 1/20 0.38
PRKACG P22612 1/20 0.38
PRKACB P22694 1/20 0.38
TNK2 Q07912 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1522005 0.96 FGFR4 (0.39) KDRBRAFKRASRAF1MAP2K2
SCHEMBL1521746 0.90 FGFR4 (0.47) KDREGFRFGFR4FGFR1FGFR2
SCHEMBL1521898 0.84 FGFR4 (0.35) KDRBRAFKRASRAF1EGFR
SCHEMBL1522038 0.76 BRAF (0.48) KDRBRAFKRASRAF1MAP2K2
SCHEMBL1521380 0.75 KDR (0.36) KDRBRAFKRASRAF1MAP2K2
SCHEMBL1521664 0.74 ABL1 (0.42) FGFR4TNK2MAP4K2
SCHEMBL1522001 0.73 BRAF (0.44) KDRBRAFKRASRAF1MAP2K2
SCHEMBL1521747 0.73 KIT (0.38) KDRBRAFKRASRAF1MAP2K2
SCHEMBL1521836 0.72 KDR (0.34) KDRBRAFKRASRAF1MAP2K2
SCHEMBL1522022 0.72 ABL1 (0.39) KDRBRAFKRASRAF1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KDR 500/4885BRAF 1/4885KRAS 30/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KDR 500/4885BRAF 1/4885KRAS 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.